RU2016151420A - Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий - Google Patents
Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий Download PDFInfo
- Publication number
- RU2016151420A RU2016151420A RU2016151420A RU2016151420A RU2016151420A RU 2016151420 A RU2016151420 A RU 2016151420A RU 2016151420 A RU2016151420 A RU 2016151420A RU 2016151420 A RU2016151420 A RU 2016151420A RU 2016151420 A RU2016151420 A RU 2016151420A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- aryl
- compound according
- disease
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
- C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (59)
1. Соединение формулы (I), либо его фармацевтически приемлемая соль:
где: R1 означает алкил, О-алкил, Cl, F или Br;
R2 означает Н или F;
R3 выбран из Н и алкила;
R4 выбран из Н и C(O)R6;
R5 означает Н;
или же R4 и R5 соединяются с образованием 5-6-членной насыщенной или ненасыщенной гетероциклической группы, необязательно содержащей 1 или 2 гетероатома, таких как N, в дополнение к тем атомам N, с которыми связаны R4 и R5, причем данная гетероциклическая группа необязательно замещена одной или несколькими группами R10;
R6 выбран из R7, OR7 и NR8R9;
R7, R8 и R9 каждый независимо выбран из алкила, циклоалкила, аралкила, циклоалкенила, гетероциклила и арила, каждый из которых необязательно замещен одной или несколькими группами R10;
каждый R10 независимо выбран из галогена, ОН, =O, CN, СОО-алкила, аралкила, SO2-алкила, SO2-арила, СООН, СО-алкила, СО-арила, NH2, NH-алкила, N(алкил)2, CF3, алкила и алкокси;
X и Z каждый независимо означает CR11, a Y выбран из CR11 и N;
R11 означает Н, алкил или F;
для применения при лечении заболевания, выбранного из группы лейкодистрофий, рассеянного склероза и болезни Шарко-Мари-Тута 1А (СМТ1А).
2. Соединение формулы (I) либо его фармацевтически приемлемая соль:
где: R1 означает алкил, Cl, F или Br;
R2 означает H или F;
R3 выбран из Н и алкила;
R4 выбран из Н и С(O)R6;
R5 означает Н;
или же R4 и R5 соединяются с образованием 5-6-членной насыщенной или ненасыщенной гетероциклической группы, необязательно содержащей 1 или 2 гетероатома, таких как N, в дополнение к тем атомам N, с которыми связаны R4 и R5, причем данная гетероциклическая группа необязательно замещена одной или несколькими группами R10;
R6 выбран из R7, OR7 и NR8R9;
R7, R8 и R9 каждый независимо выбран из алкила, циклоалкила, аралкила, циклоалкенила, гетероциклила и арила, каждый из которых необязательно замещен одной или несколькими группами R10;
каждый R10 независимо выбран из галогена, ОН, CN, СОО-алкила, аралкила, SO2-алкила, SO2-арила, СООН, СО-алкила, СО-арила, NH2, NH-алкила, N(алкил)2, CF3, алкила и алкокси;
X и Z каждый независимо означает CR11, a Y выбран из CR11 и N;
R11 означает Н или F;
для применения при лечении заболевания, выбранного из группы лейкодистрофий, рассеянного склероза и болезни Шарко-Мари-Тута 1А СМТ1А.
3. Соединение по п. 1 или 2, в котором R1 означает Cl, Br, Me или F, более предпочтительно Cl.
4. Соединение по пп. 1, 2 или 3, в котором R2 означает Н.
5. Соединение по любому из предыдущих пунктов, в котором Y означает CR11.
6. Соединение по любому из предыдущих пунктов, в котором R3 и R4 оба означают Н.
7. Соединение по любому из пп. 1-6, в котором R3 означает Н, R4 означает C(O)R6, a R6 означает Me или ОМе.
8. Соединение по любому из предыдущих пунктов, выбранное из следующих:
либо их приемлемых солей.
9. Соединение по любому из предыдущих пунктов, выбранное из следующих:
либо их приемлемых солеи.
10. Соединение по п. 8, которым является соединение 1 либо его фармацевтически приемлемая соль.
11. Соединение по любому из пп. 1-9, в котором заболеванием является рассеянный склероз.
12. Соединение по любому из пп. 1-9, в котором заболеванием является лейкодистрофия, предпочтительно болезнь Пелицеуса-Мерцбахера.
13. Соединение по любому из пп. 1-7, в котором заболеванием является СМТ-1А.
14. Комбинация соединения формулы (I) либо его фармацевтически приемлемой соли:
где: R1 означает алкил, О-алкил, Cl, F или Br;
R2 означает Н или F;
R3 выбран из Н и алкила;
R4 выбран из Н и C(O)R6;
R5 означает Н;
или же R4 и R5 соединяются с образованием 5-6-членной насыщенной или ненасыщенной гетероциклической группы, необязательно содержащей 1 или 2 гетероатома, таких как N, в дополнение к тем атомам N, с которыми связаны R4 и R5, причем данная гетероциклическая группа необязательно замещена одной или несколькими группами R10;
R6 выбран из R7, OR7 и NR8R9;
R7, R8 и R9 каждый независимо выбран из алкила, циклоалкила, аралкила, циклоалкенила, гетероциклила и арила, каждый из которых необязательно замещен одной или несколькими группами R10;
каждый R10 независимо выбран из галогена, ОН, =O, CN, СОО-алкила, аралкила, SO2-алкила, SO2-арила, СООН, СО-алкила, СО-арила, NH2, NH-алкила, N(алкил)2, CF3, алкила и алкокси;
X и Z каждый независимо означает CR11, a Y выбран из CR11 и N;
R11 означает Н, алкил или F;
с соединением, усиливающим экспрессию и/или активность белка BIP, выбранным из вальпроевой кислоты или ее производных типа 2-ен-вальпроевой кислоты, трихостатина А, лития, 1-(3,4-дигидроксифенил)-2-тиоцианат-этанона и эксендина-4, для применения при лечении заболевания сетчатки, выбранного из группы наследственной дегенерации сетчатки типа цилиопатий сетчатки, пигментного ретинита, дегенерации желтого пятна, ретинопатии недоношенных, светоиндуцированной дегенерации сетчатки, отслоения сетчатки, диабетической ретинопатии и глаукомы.
15. Комбинация по п. 14, в которой соединение формулы (I) является таким, как определено в любом из пп. 1-7.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306075.4 | 2014-07-02 | ||
EP14306075 | 2014-07-02 | ||
PCT/EP2015/065161 WO2016001389A1 (en) | 2014-07-02 | 2015-07-02 | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016151420A true RU2016151420A (ru) | 2018-06-26 |
RU2016151420A3 RU2016151420A3 (ru) | 2018-11-23 |
RU2712452C2 RU2712452C2 (ru) | 2020-01-29 |
Family
ID=51162656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016151420A RU2712452C2 (ru) | 2014-07-02 | 2015-07-02 | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий |
Country Status (15)
Country | Link |
---|---|
US (2) | US10709677B2 (ru) |
EP (2) | EP3721877A1 (ru) |
JP (2) | JP6994939B2 (ru) |
KR (1) | KR102387615B1 (ru) |
CN (1) | CN107074752B (ru) |
AU (1) | AU2015282900B2 (ru) |
CA (1) | CA2951191C (ru) |
DK (1) | DK3164123T3 (ru) |
ES (1) | ES2812800T3 (ru) |
IL (1) | IL249502B (ru) |
MX (1) | MX2016016480A (ru) |
PL (1) | PL3164123T3 (ru) |
PT (1) | PT3164123T (ru) |
RU (1) | RU2712452C2 (ru) |
WO (1) | WO2016001389A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102387615B1 (ko) * | 2014-07-02 | 2022-04-18 | 인플렉티스 바이오사이언스 | 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도 |
CN107709291B (zh) | 2015-04-08 | 2021-03-12 | 医疗研究局 | 抑制剂及其应用 |
EP3618817B1 (en) | 2017-05-04 | 2023-07-12 | Stichting VUmc | Therapeutic effects of guanabenz treatment in vanishing white matter |
JP2021529729A (ja) | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | I型ifn依存性病態を処置するためのグアナベンズ又はその誘導体の使用 |
WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3541217A (en) | 1969-06-30 | 1970-11-17 | Lilly Co Eli | Omicron-chlorobenzylaminoguanidine for treating bovine ketosis |
US3982020A (en) * | 1970-03-17 | 1976-09-21 | Sandoz, Inc. | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation |
US3975533A (en) * | 1970-04-29 | 1976-08-17 | Shell Oil Company | Therapeutic agents |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
AU664710B2 (en) * | 1991-08-27 | 1995-11-30 | Upjohn Company, The | A method for treatment of metabolic disorders |
AU3166299A (en) * | 1998-04-09 | 1999-11-01 | Eisai Co. Ltd. | Arginine peptide analogs useful as fibroblast growth factor antagonists |
WO2001025192A1 (en) * | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
US7071211B2 (en) | 2002-09-27 | 2006-07-04 | Bausch & Lomb Inc. | Small organic molecules that increase the activity of gelatinase a in ocular cells |
EP1687641A2 (en) | 2003-09-25 | 2006-08-09 | Acadia Pharmaceuticals Inc. | Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
JP2005120046A (ja) * | 2003-10-20 | 2005-05-12 | Sankyo Co Ltd | ピリミジン誘導体を含有する医薬 |
FR2893844B1 (fr) * | 2005-11-28 | 2008-02-01 | Centre Nat Rech Scient | Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
EP1908464A1 (en) | 2006-10-04 | 2008-04-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
GB0623381D0 (en) | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
AU2008323947B2 (en) * | 2007-11-06 | 2014-02-20 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
CA2763327C (en) * | 2009-05-27 | 2019-04-02 | Donald W. Kufe | Inhibition 0f inflammation using antagonists of muc1 |
WO2011061340A1 (en) | 2009-11-23 | 2011-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity |
JP6371225B2 (ja) | 2012-02-24 | 2018-08-08 | ユニヴェルシテ・ドゥ・ストラスブールUniversite De Strasbourg | 網膜変性の処置のための組成物及び方法 |
GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
US10905663B2 (en) * | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
BR122021000304B1 (pt) * | 2013-05-01 | 2021-10-13 | Neoculi Pty Ltd | Composto, uso do mesmo e composição farmacêutica antibacteriana |
JP6510760B2 (ja) | 2014-03-31 | 2019-05-08 | 株式会社神戸製鋼所 | 金属基板 |
KR102387615B1 (ko) * | 2014-07-02 | 2022-04-18 | 인플렉티스 바이오사이언스 | 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도 |
-
2015
- 2015-07-02 KR KR1020167035656A patent/KR102387615B1/ko active IP Right Grant
- 2015-07-02 AU AU2015282900A patent/AU2015282900B2/en active Active
- 2015-07-02 MX MX2016016480A patent/MX2016016480A/es active IP Right Grant
- 2015-07-02 DK DK15734651.1T patent/DK3164123T3/da active
- 2015-07-02 PL PL15734651T patent/PL3164123T3/pl unknown
- 2015-07-02 EP EP20175482.7A patent/EP3721877A1/en not_active Withdrawn
- 2015-07-02 JP JP2017519998A patent/JP6994939B2/ja active Active
- 2015-07-02 CN CN201580036481.4A patent/CN107074752B/zh active Active
- 2015-07-02 EP EP15734651.1A patent/EP3164123B1/en active Active
- 2015-07-02 PT PT157346511T patent/PT3164123T/pt unknown
- 2015-07-02 US US15/316,785 patent/US10709677B2/en active Active
- 2015-07-02 RU RU2016151420A patent/RU2712452C2/ru active
- 2015-07-02 WO PCT/EP2015/065161 patent/WO2016001389A1/en active Application Filing
- 2015-07-02 CA CA2951191A patent/CA2951191C/en active Active
- 2015-07-02 ES ES15734651T patent/ES2812800T3/es active Active
-
2016
- 2016-12-12 IL IL249502A patent/IL249502B/en active IP Right Grant
-
2019
- 2019-11-12 JP JP2019204892A patent/JP7341034B2/ja active Active
-
2020
- 2020-06-03 US US16/891,708 patent/US20200289436A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10709677B2 (en) | 2020-07-14 |
EP3721877A1 (en) | 2020-10-14 |
IL249502A0 (en) | 2017-02-28 |
DK3164123T3 (da) | 2020-08-03 |
IL249502B (en) | 2020-09-30 |
EP3164123B1 (en) | 2020-05-20 |
KR102387615B1 (ko) | 2022-04-18 |
KR20170016873A (ko) | 2017-02-14 |
US20200289436A1 (en) | 2020-09-17 |
PL3164123T3 (pl) | 2020-11-16 |
WO2016001389A1 (en) | 2016-01-07 |
CN107074752B (zh) | 2021-10-26 |
AU2015282900B2 (en) | 2020-06-18 |
ES2812800T3 (es) | 2021-03-18 |
CN107074752A (zh) | 2017-08-18 |
JP2020037578A (ja) | 2020-03-12 |
EP3164123A1 (en) | 2017-05-10 |
MX2016016480A (es) | 2017-08-02 |
US20170151196A1 (en) | 2017-06-01 |
PT3164123T (pt) | 2020-07-24 |
RU2016151420A3 (ru) | 2018-11-23 |
RU2712452C2 (ru) | 2020-01-29 |
JP7341034B2 (ja) | 2023-09-08 |
AU2015282900A1 (en) | 2016-12-22 |
CA2951191C (en) | 2022-09-13 |
CA2951191A1 (en) | 2016-01-07 |
JP6994939B2 (ja) | 2022-02-04 |
JP2017521494A (ja) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
JP2019518766A5 (ru) | ||
AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
JP2016513130A5 (ru) | ||
JP2015537020A5 (ru) | ||
JP2017537940A5 (ru) | ||
JP2016503797A5 (ru) | ||
JP2016515561A5 (ru) | ||
JP2014521688A5 (ru) | ||
AR113908A1 (es) | Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
EA201591775A1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
JP2013502430A5 (ru) | ||
JP2017514910A5 (ru) | ||
JP2019535723A5 (ru) | ||
AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
BR112018016932A2 (pt) | processo para a preparação de ácido 4 -fenil -5 -alcoxicarbonil -2 -tiazol -2 -il -1,4 -diidropirimidin -6 -il[metil] -3 -oxo -5,6,8,8a -tetrahidro -1h -imidazo[1,5 -a]pirazin -2 -il] -carboxil acid | |
ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
RU2015120478A (ru) | Пери-карбинолы |